ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2026
The survival benefit of deceased donor liver transplantation using MELD 3.0: A contemporary analysis.
Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The decision to proceed with liver transplant (LT) must account for the risk of death without LT and the likelihood of survival after, a concept known as "survival benefit." A 2005 study suggested that deceased donor LT (DDLT) survival benefit is achieved at a MELD score of 15, a threshold that persists today. This study reassesses that threshold in the context of MELD 3.0. Data from all adults listed for primary single-organ LT in the UNOS/OPTN registry (January 1, 2021-March 31, 2023) were analyzed. Those undergoing living donor LT were excluded. Using sequential stratification, Cox regression models comparing mortality between LT recipients and waitlist candidates estimated hazard ratios across MELD 3.0 subgroups. Among 21,594 LT candidates (median MELD 3.0, 22, IQR 16-30), LT recipients had a 95% lower adjusted mortality risk than waitlisted candidates (HR 0.05, 95% CI 0.04-0.07, p <0.001). This survival benefit varied by MELD 3.0 score, with an advantage emerging at MELD 3.0 ≥12. At MELD 3.0 of 12-14, DDLT reduced mortality by 46% (HR 0.54, 95% CI 0.30-0.96, p =0.04), while no significant survival benefit was seen below MELD 3.0 of 12, largely due to high post-LT mortality. In this analysis of UNOS/OPTN data, DDLT conferred a survival benefit at MELD 3.0 scores ≥12, revising the historical threshold of 15. However, MELD 3.0 alone does not capture the full complexity of LT candidacy. Factors such as refractory ascites, hepatic encephalopathy, frailty, and poor quality of life should also be considered when considering LT for the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.